In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Executive Summary

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Advertisement

Related Content

Takeda Gets Serious About Regen Medicine With TiGenix Buy
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mesoblast Seeks New Partner In Chronic Heart Failure, To Replace Teva
How Are Japan’s Regenerative Meds Regs Playing Out?
Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling
Levin Resigns Unexpectedly, Street Grills Teva’s Chairman On Viability Of Corporate Governance

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel